Literature DB >> 10688745

Inter-study variability in population pharmacokinetic meta-analysis: when and how to estimate it?

S Laporte-Simitsidis1, P Girard, P Mismetti, S Chabaud, H Decousus, J P Boissel.   

Abstract

Population pharmacokinetic analysis is being increasingly applied to individual data collected in different studies and pooled in a single database. However, individual pharmacokinetic parameters may change randomly from one study to another. In this article, we show by simulation that neglecting inter-study variability (ISV) does not introduce any bias for the fixed parameters or for the residual variability but may result in an overestimation of inter-individual (IIV) variability, depending on the magnitude of the ISV. Two random study-effect (RSE) estimation methods were investigated: (i) estimation, in a single step, of the three-nested random effects (inter-study, inter-individual and residual variability); (ii) estimation of residual variability and a mixture of ISV and IIV in the first step, then separation of ISV from IIV in the second. The one-stage RSE model performed well for population parameter assessment, whereas, the two-stage model yielded good estimates of IIV only with a rich sampling design. Finally, irrespective of the method used, ISV estimates were valid only when a large number of studies was pooled. The analysis of one real data set illustrated the use of an ISV model. It showed that the fixed parameter estimates were not modified, whether an RSE model was used or not, probably because of the homogeneity of the experimental designs of the studies, and suggest no study-effect in this example. Copyright 2000 Wiley-Liss, Inc.

Mesh:

Year:  2000        PMID: 10688745     DOI: 10.1002/(SICI)1520-6017(200002)89:2<155::AID-JPS3>3.0.CO;2-2

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  17 in total

1.  Longitudinal aggregate data model-based meta-analysis with NONMEM: approaches to handling within treatment arm correlation.

Authors:  Jae Eun Ahn; Jonathan L French
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-04-01       Impact factor: 2.745

2.  Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics.

Authors:  Elin Svensson; Jan-Stefan van der Walt; Karen I Barnes; Karen Cohen; Tamara Kredo; Alwin Huitema; Jean B Nachega; Mats O Karlsson; Paolo Denti
Journal:  Br J Clin Pharmacol       Date:  2012-09       Impact factor: 4.335

Review 3.  Recommended reading in population pharmacokinetic pharmacodynamics.

Authors:  Peter L Bonate
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

4.  Non-Bayesian knowledge propagation using model-based analysis of data from multiple clinical studies.

Authors:  Jakob Ribbing; Andrew C Hooker; E Niclas Jonsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-11-08       Impact factor: 2.745

5.  Modelling and simulation of the Positive and Negative Syndrome Scale (PANSS) time course and dropout hazard in placebo arms of schizophrenia clinical trials.

Authors:  Venkatesh Pilla Reddy; Magdalena Kozielska; Martin Johnson; Ahmed Abbas Suleiman; An Vermeulen; Jing Liu; Rik de Greef; Geny M M Groothuis; Meindert Danhof; Johannes H Proost
Journal:  Clin Pharmacokinet       Date:  2012-04-01       Impact factor: 6.447

6.  Inter-study variability of preclinical in vivo safety studies and translational exposure-QTc relationships--a PKPD meta-analysis.

Authors:  V Gotta; F Cools; K van Ammel; D J Gallacher; S A G Visser; F Sannajust; P Morissette; M Danhof; P H van der Graaf
Journal:  Br J Pharmacol       Date:  2015-07-21       Impact factor: 8.739

7.  Population Pharmacokinetic Model of Doxycycline Plasma Concentrations Using Pooled Study Data.

Authors:  Ashley M Hopkins; Jessica Wojciechowski; Ahmad Y Abuhelwa; Stuart Mudge; Richard N Upton; David J R Foster
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

8.  Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition.

Authors:  A A Moghadamnia; A Rostami-Hodjegan; R Abdul-Manap; C E Wright; A H Morice; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

9.  External evaluation of population pharmacokinetic models for ciclosporin in adult renal transplant recipients.

Authors:  Jun-Jun Mao; Zheng Jiao; Hwi-Yeol Yun; Chen-Yan Zhao; Han-Chao Chen; Xiao-Yan Qiu; Ming-Kang Zhong
Journal:  Br J Clin Pharmacol       Date:  2017-11-03       Impact factor: 4.335

10.  Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability.

Authors:  Thomas Kerbusch; Ulrika Wählby; Peter A Milligan; Mats O Karlsson
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.